ST6GAL1 and triple-negative breast carcinoma: ST6GAL1 correlates with advanced stage, chemoresistance, and metastatic recurrence [139], with therapeutic targeting of ST6Gal-1-high triple-negative breast cancer stem cells demonstrating improved efficacy through glycan engineering approaches [140].